Virax Biolabs Group Limited - Ordinary Shares (VRAX)
Healthcare › In Vitro & In Vivo Diagnostic Substances
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 0.16 — trading below book value
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -111.1%
- Revenue declining 96% annually
Virax Biolabs Group Limited - Ordinary Shares (VRAX) is a Healthcare company operating in In Vitro & In Vivo Diagnostic Substances, listed on the NASDAQ , with a market capitalisation of $1 million . Key value metrics: P/B ratio 0.16, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Virax Biolabs Group Limited - Ordinary Shares — Fundamental Analysis Summary
On financial health, VRAX shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -111.1% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.06.
StockPik's composite Value Score for VRAX is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VRAX reports a thin gross margin of -838.2% (sector average: 33.5%) and a negative operating margin of -97,344.8%.
VRAX shows revenue declining at 96% year-over-year, with earnings growing at 10%.